All In Biotech

Drug Trial Radar · NCT05303402

A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.

A Phase IIb/III, Open Label, Single Arm, Multi-centre, Trial to Assess the Immunogenicity and Safety of an Additional Dose Vaccination With a Recombinant Protein RBD Fusion Heterodimer Candidate (PHH-1V) Against SARS-CoV-2, in Adults With Pre-existing Immunosuppressive Conditions Vaccinated Against COVID-19

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

240

Actual

Start

May 12, 2022

Primary completion

Jan 9, 2024

Study completion Jan 9, 2024

Sponsor

Lead sponsor
Hipra Scientific, S.L.UIndustry
Sponsor type
Industry
Collaborators
Veristat, Inc.; Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia; Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta; Asphalion
First posted
Mar 31, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase IIb/III, open label, single arm, multi-centre, trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) against SARS-CoV-2, in adults with pre-existing immunosuppressive conditions vaccinated against COVID-19

Conditions

  • SARS CoV 2 Infection

Interventions

  • PHH-1VBiological

    COVID-19 Vaccine HIPRA, 40 mcg/dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Immunogenicity against Omicron, Beta, Delta at Day 0 and Day 14Time frame: Day 0 and Day 14

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Hospital Germans Trias i Pujol

    Badalona, Barcelona, Spain

  • Hospital Clínic de Barcelona

    Barcelona, Barcelona, Spain

  • Hospital Josep Trueta

    Girona, Girona, Spain

  • Hacettepe University Medical Faculty Hospitals

    Ankara, Ankara, Turkey (Türkiye)

  • Ankara University Medical Faculty Hospitals

    Ankara, Ankara, Turkey (Türkiye)

  • Koc University Hospital

    Istanbul, Istanbul, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.